BioNTech: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
kTidak ada ringkasan suntingan Tag: VisualEditor Suntingan perangkat seluler Suntingan peramban seluler |
kTidak ada ringkasan suntingan Tag: VisualEditor Suntingan perangkat seluler Suntingan peramban seluler |
||
Baris 38:
Perusahaan ini juga mengembangkan sebuah [[modRNA|terapeutik manusia berbasis mRNA]] melalui injeksi intravena untuk dapat membawa [[imunoterapi]] [[kanker]] berbasis mRNA individual ke tahap [[uji klinis]], serta untuk mendirikan proses produksinya sendiri.<ref name="SEC report">{{Citation|language=en|author=BioNTech SE|url=https://sec.report/Document/0001193125-19-241112/|title=Form F-1|publisher=[[United States Securities and Exchange Commission|U.S. Securities and Exchange Commission]]|date=9 September 2019|access-date=23 September 2020}}</ref>
Pada tahun 2020, BioNTech bermitra dengan [[Pfizer]] untuk pengujian dan logistik, dalam mengembangkan [[vaksin RNA]] [[vaksin COVID-19 Pfizer–BioNTech|BNT162b2]] untuk mencegah penularan [[COVID-19]]. Vaksin tersebut menawarkan efikasi sebesar 95% dalam mencegah terjadinya penularan COVID-19 setidaknya 7 hari setelah pemberian dosis kedua.<ref>{{cite report |title=Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA Briefing Document – Pfizer-BioNTech COVID-19 Vaccine |url=https://www.fda.gov/media/144245/download |access-date=2021-07-04 }}</ref> Pada tanggal 2 Desember 2020, otorisasi [[Human Medicines Regulations 2012|HMR]] sementara diterbitkan oleh [[Pemerintah Britania Raya]] untuk [[BNT162b2|vaksinasi BNT162b2]] di [[Britania Raya]].<ref name="uk12-2a">{{cite web |title=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/940728/Conditions_of_Authorisation_for_Pfizer_BioNTech_COVID-19_vaccine.pdf |date=2 December 2020 |publisher=Government of the United Kingdom |access-date=2 December 2020 |language=en}}</ref><ref name="uk12-2">{{cite web |title=UK medicines regulator gives approval for first UK COVID-19 vaccine |url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine |date=2 December 2020 |publisher=Government of the United Kingdom |access-date=2 December 2020 |language=en}}</ref> BNT162b2 adalah vaksin mRNA pertama yang diotorisasi. Beberapa hari kemudian, vaksin tersebut juga mendapat persetujuan darurat di Amerika Serikat,<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions|url=https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/pfizer-biontech-covid-19-vaccine-frequently-asked-questions|access-date=22 December 2020}}</ref> Kanada,<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 vaccine: What you should know|date=9 December 2020|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html|access-date=22 December 2020}}</ref> dan [[Swiss]].<ref>{{Citation|language=en|title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland|url=https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff_erstzulassung.html|access-date=22 December 2020}}</ref> Pada tanggal 21 Desember 2020, [[Komisi Eropa]] menyetujui vaksin koronavirus BioNTech/Pfizer sesuai rekomendasi positif dari [[European Medicines Agency]] (EMA).<ref>{{Cite web|date=21 December 2020|title=Commission approves BioNTech/Pfizer vaccine|url=https://www.politico.eu/article/european-commission-approves-biontech-pfizer-vaccine/|access-date=22 December 2020|website=Politico|language=en-US}}</ref>
== Sejarah ==
| |||